Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer

• Published in: Journal of controlled release 2024-02, Vol.366, p.395-409
• Main Authors: Chen, Ying, Gong, Liang, Cao, Yulin, Liu, Zhiang, Wang, Yuanben, Cheng, Han, Feng, Yuyang, Yao, Surui, Yin, Yuan, Wu, Zhimeng, Huang, Zhaohui
• Format: Article
• Language: English
• Subjects: Animals; Cancer immunotherapy; Exosomes; Macrophages; Mice; Milk; Milk exosomes; Nanobody; Neoplasms - therapy; PDL1; Tumor Microenvironment; Tumor-Associated Macrophages
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2023.12.058

Tumor-associated macrophages (TAMs) play a key role in inducing an immunosuppressive tumor microenvironment (TME) and cancer immune escape. We previously revealed that PDL1 (a key immune checkpoint) was upregulated in TAMs and induced M2 polarization, highlighting PDL1 in TAMs as a promising cancer therapeutic target. In this study, we developed an engineered milk exosome (mExo) system decorated with M2pep (an M2 macrophage binding peptide) and 7D12 (an anti-EGFR nanobody) (7D12-mExo-M2pep-siPDL1) to specifically deliver siPDL1 into M2 TAMs. A series of in vitro and in vivo assays showed that the dually targeted engineered mExos efficiently delivered siPDL1 into M2 TAMs and repolarized them into M1 macrophages, restoring CD8+ T cell immune activity and remodeling TME. Importantly, systemically administered 7D12-mExo-M2pep-siPDL1 showed efficient single-agent antitumor activity, resulting in nearly 90% tumor growth inhibition in a mouse model of orthotopic epidermal growth factor receptor (EGFR) cancer. Collectively, our study indicates that PDL1 is a promising target for TAM-based cancer immunotherapy, and our engineered mExo-based nanomedicine represents a novel tool for specifically targeting M2 TAMs, distinguishing this novel therapeutic method from other TAM-targeting therapies and highlighting its promising clinical potential. [Display omitted] •An engineered mExo system decorated with M2pep and EGFR nanobody was developed.•PDL1 is a promising target for TAM-based cancer immunotherapy.•The engineered mExo system specifically deliver siPDL1 into M2 TAMs.•The engineered mExo system showed efficient antitumor activity for EGFR+ tumors.